10 Jul How to Spot Hormone Changes Without Overthinking It
Supplement, Peptide & Hormone Therapy Notice: The hormone therapy options referenced in this article should only be undertaken under the supervision of a qualified, licensed healthcare provider following a thorough clinical assessment. Hormone therapies may interact with existing medications and may be contraindicated in individuals with certain health conditions. Do not use hormone therapies if you are pregnant, nursing, or may become pregnant. Always consult your physician before beginning, modifying, or discontinuing any hormone protocol.
Hormone changes can be sneaky. One week you feel mostly normal, and the next you're wide awake at 3 a.m., wondering why your body suddenly forgot the rules. It's easy to shrug off odd symptoms and blame stress, age, or a busy schedule. Sometimes that's true. Sometimes it's not. If you've been feeling a little off and can't quite explain why, it helps to know what signs to watch for and when it might be worth getting real support. For anyone in Grand Rapids weighing that question, local clinicians can run the bloodwork that turns guesswork into a clear answer.
For broader context on how hormone therapy is used to manage symptoms and improve quality of life, see this overview of hormone therapy benefits and considerations.
[caption id="attachment_74948" align="aligncenter" width="500"]
Source: Pexels[/caption]
Dr. Bradshaw[/caption]
Catriona Bradshaw MMBS(Hons), PhD, FAChSHM, FAHMS
Professor (Research), Head of Research Translation and Mentorship
and of The Genital Microbiota and Mycoplasma Group Melbourne
School of Translational Medicine, Monash University and Alfred Hospital
Principal Research Fellow at the Burnet Institute
MedicalResearch.com: What is the background for this study?
Response: One in three women globally have bacterial vaginosis (BV), a condition that causes a malodourous discharge, and associated with serious gynaecologic and obstetric sequelae (including miscarriage and preterm birth) and increases the risk sexually transmitted infections (STIs) and HIV. Women with symptoms are treated with broad-spectrum antibiotics, however, over 50% of women experience BV recurrence within 3-6 months. The recurrence rate is even higher at 60-80% among women with an ongoing regular partner. Current practice is to simply retreat women experiencing BV recurrence with the same antibiotics, which leaves them (and clinicians) frustrated and distressed.
We and others have accumulated a body of evidence to show that BV has the profile of an STI. BV-associated bacteria are detected in men in the distal urethra and on penile-skin, and couples share these organisms. However, to date, has not been recommended for BV as it is for other STIs. This is largely because men do not usually have any symptoms, and past partner-treatment trials in the 1980s and 1990s, which only used oral antibiotics for men, failed to prevent BV recurrence, which was taken as conclusive evidence against sexual transmission. Reviews of these trials have since identified their limitations.
Given the evidence of male carriage of BV-associated bacteria at two genital sites, we hypothesised that both sites needed to be targeted with antimicrobial therapy to prevent re-infection post-treatment. The aim of our study was to assess if male partner-treatment concurrently with female treatment using a combination of oral and topical antibiotics for the first time, would decrease BV recurrence over 12 weeks compared to the current standard practice of treating women only.
John W. Ayers, PhD, MA
Altman Clinical Translational Research Institute
University of California
San Diego, La Jolla
MedicalResearch.com: What is the background for this study?
Response: Crisis pregnancy centers (CPCs) are frequently at the center of news
and policy debates, yet little data exists about where they operate or
what they actually do. To address this gap, we developed
Dr. Fink[/caption]
Dorothy A. Fink, MD
Deputy Assistant Secretary for Women's Health
Director, Office on Women's Health
US Department of Health & Human Services
Rockville, MD
MedicalResearch.com: What is the background for this study?
Response: Delivery-related mortality in U.S. hospitals has decreased for all racial and ethnic groups, age groups, and modes of delivery while the prevalence of severe maternal mortality (SMM) increased for all patients, with higher rates for racial and ethnic minority patients of any age.
This study specifically looked at inpatient delivery-related outcomes and found a 57% decrease from 2008-2021. The decreasing mortality rates within the inpatient delivery setting demonstrated as statistically significant and a welcome finding for all women.
This study also looked with greater granularity at the impact of race, ethnicity, and age. Mortality for American Indian women decreased 92%, Asian women decreased 73%, Black women decreased 76%, Hispanic women decreased 60%, Pacific Islander women decreased 79%, and White women decreased 40% during the study period.